December 10th 2024
Sophia Humphreys, PharmD, MHA, BCBBS, a practicing pharmacist and health system director at Sutter Health, discussed the decision-making process for selecting between fixed-duration options and continuous Bruton tyrosine kinase inhibitor (BTKi) therapy for patients with chronic lymphocytic leukemia (CLL).
December 4th 2024
Watch the series now!
COVID-19's Potential Impact on Advanced-Stage Lung Cancer Trends